Nicola Dalbeth
banner
nicoladalbeth.bsky.social
Nicola Dalbeth
@nicoladalbeth.bsky.social
Rheumatologist, Tāmaki Makaurau
Reposted by Nicola Dalbeth
📢 New Publication Alert!

📝 Title: The Fast-Evolving Landscape of Treatments for Calcium Pyrophosphate Deposition Disease!

👥 Authors: Vicky Tai, Charlotte Jauffret, @nicoladalbeth.bsky.social and Tristan Pascart

🔗 Read the full article here: www.mdpi.com/2813-4583/3/...

#CPPD #gout
www.mdpi.com
November 25, 2025 at 11:43 AM
Reposted by Nicola Dalbeth
Investigating whether fractional excretion of urate (FEUA) modulates urate-lowering response to allopurinol showed that allopurinol was modestly more effective in patients with low FEUA, likely due to decreased oxypurinol renal clearance

Arthritis Care & Research
doi.org/10.1002/acr....

#Medsky
November 20, 2025 at 5:38 PM
Reposted by Nicola Dalbeth
Colchicine initiation after gout diagnosis associated with modestly (12%) lower risk of total joint arthroplasty (vs. those who did not initiate colchicine)

UK population-based cohort study (IQVIA Medical Research Database)

Arthritis & Rheumatology
doi.org/10.1002/art....

#Medsky
November 17, 2025 at 9:55 PM
Reposted by Nicola Dalbeth
Excited to share the results of the TeMPO (Treatment of Meniscal Problems in Osteoarthritis) trial, published today in NEJM: www.nejm.org/doi/full/10....

A labor of love from the #BWH #oracore team, with partners in Buffalo, Pittsburgh, and Cleveland. 879 randomized with the COVID in the middle!
A Randomized Trial of Physical Therapy for Meniscal Tear and Knee Pain | NEJM
Physical therapy is routinely recommended for knee pain attributed to a degenerative meniscal tear, but its efficacy has not been established. We randomly assigned participants 45 to 85 years of ag...
www.nejm.org
October 31, 2025 at 6:15 PM
Reposted by Nicola Dalbeth
🌟Meet Dr. Francisca Sivera, the new EULAR Education Committee Chair!

She assumes this role with a strong commitment to collaborating with diverse professionals to advance high-quality rheumatology training across Europe.

Watch the full interview here: https://pulse.ly/p3iftscuzf
October 23, 2025 at 8:01 PM
Reposted by Nicola Dalbeth
The #GCAN2025 Gold Medal Award goes to Tony Merriman of UAB for his work, his mentorship, and his service

My favorite are these talks where we hear about someone's career but also their reflections on what has mattered

#ACR25
October 23, 2025 at 1:35 PM
Reposted by Nicola Dalbeth
Tony Merriman gives shoutout to @nicoladalbeth.bsky.social "who proudly told me last week that she would sleep through my talk" 😆

I mean, it's like 2am in NZ right now

#GCAN2025
October 23, 2025 at 1:38 PM
Reposted by Nicola Dalbeth
Great start to #GCAN2025 with strong representation from STOP-Gout trial, fun great debate (with hats), proud of mentee presentations, & great to see collaborators in person with #Burt
@rheumcat.bsky.social @nicoladalbeth.bsky.social
October 23, 2025 at 4:33 AM
Reposted by Nicola Dalbeth
Outcomes
#GCAN2025 year in review

Liu et al
RCTs and registries for gout are not representative of the US population and tx effects may not be generalizable

#ACR25
October 22, 2025 at 1:46 PM
Reposted by Nicola Dalbeth
Chair Dr Bob Terkeltaub shows the growth of this meeting @g-cangout.bsky.social #GCAN2025

Thanks for continuing to have this meeting as hybrid, even if the meeting is right before #ACR25

Taking a week + out for travel is often not possible
October 22, 2025 at 1:05 PM
Reposted by Nicola Dalbeth
idk, that felt like a really effective debate strategy from @nicoladalbeth.bsky.social 🧢

#GCAN2025 #ACR25
October 22, 2025 at 7:05 PM
Reposted by Nicola Dalbeth
Dalbeth rebuttal:
-data presented do not represent the average pt with gout

Final vote: 61% vote no

#GCAN2025 #ACR25
October 22, 2025 at 7:14 PM
Reposted by Nicola Dalbeth
⭐CPPD nomenclature - Silvia Sirotti and Georgios Filippou

We are deep in the Delphi rounds right now and I must confess I no longer remember what each P and each D stands for at this point 😵‍💫

(And I thought axSpA nomenclature discussions were wild)

#GCAN2025 #ACR25
October 22, 2025 at 9:47 PM
Reposted by Nicola Dalbeth
Dr. Tim Kwok emphasized that “difficult-to-treat gout” goes beyond urate levels, involving persistent inflammation, reduced function, and higher healthcare use. A holistic approach addressing clinical, patient, and system factors is key. #2025GCAN #Gout #Rheumatology
October 22, 2025 at 9:47 PM
Reposted by Nicola Dalbeth
#GCAN2025 Great Debate: : The Standard Serum Urate Target in Gout Should Be < 5mg/dL for the Average Patient

Pro: Thomas Bardin
Con: @nicoladalbeth.bsky.social

Audience pre-vote in support of the statement

#ACR25
October 22, 2025 at 6:33 PM
Reposted by Nicola Dalbeth
Post hoc analysis of the COLCHICORT trial (colchicine vs prednisone for acute CPP crystal arthritis) identified factors predictive of arthritis resolution. Prednisone appeared to perform better in achieving pain relief after 2 days of treatment

AC&R
doi.org/10.1002/acr....

#Medsky
September 9, 2025 at 12:39 PM
Reposted by Nicola Dalbeth
Mouse model study found short-term intermittent fasting prevented crystal-induced inflammation & induced production of anti-inflammatory metabolites, such as ketone body BHB, corticosterone, & spermidine. Spermidine supplementation reproduced anti-inflammatory effects

A&R
doi.org/10.1002/art....
September 4, 2025 at 9:04 PM
Reposted by Nicola Dalbeth
International survey study of people with asymptomatic hyperuricemia looked at perceptions about hyperuricemia and urate-lowering therapy. Hyperuricemia was not well understood, and most perceived minimal consequences of asymptomatic hyperuricemia

AC&R
doi.org/10.1002/acr....

#Medsky
September 3, 2025 at 4:22 PM
Reposted by Nicola Dalbeth
Thanks to @medscape.com for highlighting our work

www.medscape.com/viewarticle/...
August 20, 2025 at 12:08 AM
Reposted by Nicola Dalbeth
Target trial emulations compared CV safety of NSAIDs vs colchicine among patients with gout starting allopurinol, and found NSAID prophylaxis was associated with higher risk of CV events than colchicine or no prophylaxis

Arthritis & Rheumatology
doi.org/10.1002/art....

#Medsky #Rheumsky
June 3, 2025 at 8:33 PM
Reposted by Nicola Dalbeth
✨July Issue✨| Factors beyond urate levels for managing gout flares

In this Comment article, the authors highlight the importance of considering factors beyond urate levels to prevent gout flares and improve the quality of life of individuals with gout.

bit.ly/4liJVTL

#Rheumsky #Medsky
Factors beyond urate levels for managing gout flares - Nature Reviews Rheumatology
Urate crystals alone are required but not sufficient to trigger gout flares; they can also be modulated by environmental, metabolic, genetic and epigenetic factors. Avoiding large variation in urate l...
bit.ly
June 26, 2025 at 8:54 AM
Reposted by Nicola Dalbeth
Addressing patients’ expectations can enhance treatment outcomes and reduce adverse effects.

This JAMA Insights offers four communication strategies to improve clinician-patient interactions.

ja.ma/3Hsek2L #MedSky #MedEd
June 4, 2025 at 4:06 PM
Reposted by Nicola Dalbeth
Phase 3 RCT in Chinese patients with gout showed dotinurad 4 mg/day was superior to febuxostat 40 mg/day in achieving serum urate levels ≤6.0 mg/dL at week 24. Treatment-emergent AE incidence was similar between treatment groups

Arthritis & Rheumatology
doi.org/10.1002/art....

#Medsky
June 3, 2025 at 12:23 PM
Reposted by Nicola Dalbeth
Feels like a good time to share this - Don McGlashan playing Anchor Me last week for RNZ, a stunning version

youtu.be/qlAJjSpi5T0?...
Don McGlashan - Anchor Me (Live at RNZ)
YouTube video by RNZ Music
youtu.be
May 31, 2025 at 9:30 AM
Reposted by Nicola Dalbeth
Arthritis Care & Research June Editor's Pick

👉 Gout Flares After Stopping Anti-Inflammatory Prophylaxis: A Rapid Literature Review and Meta-Analysis

doi.org/10.1002/acr....
May 31, 2025 at 4:51 PM